Neoplasms

All Conditions

Rare Diseases

Sarcoma

Neoplasms, Connective and Soft Tissue

Neoplasms by Histologic Type

Soft Tissue Sarcoma

All Drugs and Chemicals

Antibodies

Antibodies, Bispecific

Immunoglobulins

Immunologic Factors

Cardunolizumab 6mg/kg was administered every 2 weeks, with the first evaluation at 8 weeks of treatment and subsequent evaluations every 12 weeks.

Cardunilizumab

bin Li, doctor

The goal of this type of study: clinical trial is to observe the efficacy and safety of cardunilizumab in soft tissue sarcomas after failure of at least first-line anthracycline-based chemotherapeutic agents, including undifferentiated sarcoma (UPS), smooth muscle sarcoma, mucinous fibrosarcoma, and poorly differentiated/undifferentiated/polymorphic liposarcoma, etc.) . The main question\[s\] it aims to answer are:

* Cardunilizumab is effective in soft tissue sarcomas after failure of at least first-line anthracycline-based chemotherapeutic agents, including undifferentiated sarcoma (UPS),smooth muscle sarcoma, mucinous fibrosarcoma, and poorly differentiated/undifferentiated/polymorphic liposarcoma) is effective .
* Cardunilizumab has manageable adverse effects. Participants will be given Cardunolizumab 6mg/kg once every 2 weeks free

Some important factors for applying for this clinical trial:

1. sarcomas are dangerous, subtypically complex, and lack effective treatment. Soft Tissue Sarcoma treatment is looking for new drugs to improve patient prognosis.
2. PD-1 inhibitor monotherapy has shown initial efficacy in some soft tissue sarcoma subtypes.
3. Dual immunotherapy targeting PD-1 and CTLA-4 is more effective in the treatment of malignant tumors.
4. The "two-in-one" dual-antibody cardunculizumab, which is more potent and less toxic, has been approved for marketing by the Fast Track Review.
5. We hypothesize that the treatment of soft tissue sarcoma with cadunilizumab is safer and more effective than currently available immunotherapy options; however, this has not yet been reported.

Efficacy and Safety Study of Cardunilizumab in Soft Tissue Sarcoma

Efficacy and Safety Study of Cardunolizumab in Soft Tissue Sarcoma After Failure of at Least Anthracycline-based Chemotherapy: a Single-arm Clinical Trial

we will share the some dates to the website:http://www.medresman.org.cn/login.aspx or publication of results of clinical trials in the form of papers

Immunohistochemical testing values for all patients were completed by our pathology department

Tumor volume reduction of up to 30%（According to RECIST 1.1 efficacy evaluation criteria）

according to criteria CTCAE 5.0,the ratio of AE and SAE which were defined by the common terminology criteria for adverse events,CTCAE.

Adverse effects due to the use of immunotherapy

Time from initiation of immunotherapy to death or time lost to visit.

Time from initiation of immunotherapy to disease progression or death from other causes.

Spots Global Cancer Trial Database for cardunilizumab